Transcatheter Arterial Micro-Embolization (TAME) Using Nexsphere-F in Patients With Chronic Pain in Elbow or Wrist

Last updated: March 21, 2024
Sponsor: Next Biomedical Co., Ltd.
Overall Status: Active - Recruiting

Phase

N/A

Condition

Osteoarthritis

Chronic Pain

Pain

Treatment

Transcatheter Arterial Micro-Embolization

Clinical Study ID

NCT06207851
NS-F TAME002
  • Ages 19-80
  • All Genders

Study Summary

In patients with chronic elbow or wrist pain, the pain is controlled by conventional conservative therapy The pain reduction effect of Nexsphere-F embolization in patients who need additional treatment It is intended to demonstrate safety.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Those aged 19 to 80
  2. Anyone who can provide a consent form
  3. A person with a life expectancy of at least 12 months
  4. Those who have not responded or failed in preservation treatment for at least threemonths(e.g. NSAIDS/physical therapy/steroidal joint injections, etc.)
  5. VAS score of 4 or higher and moderate-severe elbow or wrist pain

Exclusion

Exclusion Criteria:

  1. Those with a VAS Score of less than 4 and Mild Elbow or Wrist Pain
  2. Chronic Renal Insufficiency(Serum creatinine > 2mg/dL)
  3. allergy to iodide contrast agents that do not respond to steroids
  4. Those with acute infection or malignancy
  5. Those who have previously had elbow or wrist surgery
  6. Those with Bleeding Diabetes that cannot be calibrated

Study Design

Total Participants: 38
Treatment Group(s): 1
Primary Treatment: Transcatheter Arterial Micro-Embolization
Phase:
Study Start date:
July 13, 2023
Estimated Completion Date:
July 13, 2026

Study Description

This clinical trial is a single cancer, single center, open label, and pilot clinical trial that demonstrates the performance and safety of Nexsphere-F for patients aged 19 to 80 who need additional treatment because their pain is not controlled even after taking existing treatments.

In addition, through this clinical trial, complications of embolization and Nexsphere-F and It checks the safety of side effects. Therefore, in this study, TAME treatment for patients with chronic elbow pain 2 to 7 months, 1 month later, 3 months, 6 wah VAS score reductions and QuickDASH scores, PRTEE score primary 6 Evaluate the reduction rate of medication, discontinuation rate of combination therapy, and occurrence of abnormal cases during the follow-up period. For patients with chronic wrist pain, VAS score after 2 to 7 days, 1 month, 3 months, and 6 months of TAME treatment QuickDASH score reduction rate, drug reduction rate after 6 months, discontinuation rate of combination therapy, and follow-up period the investigators will evaluate the effectiveness and safety of Nexsphere-F by evaluating whether abnormal cases occur during the period.

Connect with a study center

  • Konkuk Hospital

    Seoul, Kwang Jin Gu 120-1
    Korea, Republic of

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.